DaVita Inc. (DVA): Price and Financial Metrics


DaVita Inc. (DVA)

Today's Latest Price: $89.70 USD

0.14 (0.16%)

Updated Oct 20 4:00pm

Add DVA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 70 in Medical - Services

See all "A" rated Strong Buy stocks

DVA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for DVA is 5.35 -- better than 92.07% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 8.38 for Davita Inc; that's greater than it is for 87.92% of US stocks.
  • In terms of volatility of its share price, DVA is more volatile than only 1.67% of stocks we're observing.
  • Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are AMCX, IRM, MTZ, CWST, and RRR.
  • DVA's SEC filings can be seen here. And to visit Davita Inc's official web site, go to www.davita.com.

DVA Stock Price Chart Interactive Chart >

Price chart for DVA

DVA Price/Volume Stats

Current price $89.70 52-week high $92.67
Prev. close $89.56 52-week low $56.99
Day low $89.41 Volume 617,125
Day high $90.68 Avg. volume 1,275,408
50-day MA $86.61 Dividend yield N/A
200-day MA $81.31 Market Cap 10.94B

DaVita Inc. (DVA) Company Bio


DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.

DVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$89.70$290.31 224%

Below please find a table outlining a discounted cash flow forecast for DVA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Davita Inc ranked in the 70th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 225.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Davita Inc ended up being:

  • As a business, DVA is generating more cash flow than 85.43% of positive cash flow stocks in the Healthcare.
  • 46% of the company's capital comes from equity, which is greater than only 24.35% of stocks in our cash flow based forecasting set.
  • Davita Inc's weighted average cost of capital (WACC) is 6%; for context, that number is higher than merely 1.53% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%218%
1%221%
2%224%
3%227%
4%231%
5%234%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DVA, try PDEX, NVO, SGRY, ALXN, and LXRX.


DVA Latest News Stream


Event/Time News Detail
Loading, please wait...

DVA Latest Social Stream


Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about Davita Inc that investors may wish to consider to help them evaluate DVA as an investment opportunity.

DaVita slips 3% on reported Humana snub

Dialysis services provider DaVita ([[DVA]] -3.3%) ended the day in the red, although up 2.4% from the session low of $80.87, on reports that Humana ([[HUM]] +0.5%) has dropped it from its provider network for 2021. ...

Seeking Alpha | October 1, 2020

Insider Weekends: Henry Samueli Buys $37 Million Worth Of Broadcom

Insider buying increased last week. Notable Insider Buys: Broadcom Inc., TravelCenters of America Inc., Kingsway Financial Services Inc., DaVita Inc., CB Financial Services, Inc.

Seeking Alpha | September 28, 2020

Berkshire Hathaway reduced stake in DaVita HealthCare Partners Inc

https://www.investing.com/news/stock-market-news/berkshire-hathaway-reduced-stake-in-davita-healthcare-partners-inc-2302610

Investing.com | September 21, 2020

DaVita Announces Final Results Of Self-Tender Offer

DENVER, Sept. 17, 2020 /PRNewswire/ -- DAVITA INC. (NYSE: DVA) ("DaVita") a health care provider focused on transforming care delivery to improve quality of life for patients globally and one of the largest providers of kidney care services in the United States, announced today the final…

PR Newswire | September 17, 2020

DaVita reports preliminary results of self-tender offer

DaVita (DVA) announces the preliminary results of its modified "Dutch auction" tender offer for up to $1B of its common stock at a price between $77.00 and $88.00, which expired at 12:00 midnight, NYC time, on September 14. A total of 8,000,679 shares were validly tendered and not withdrawn at or below $88.00/share, including 3,388,259 shares...

Seeking Alpha | September 15, 2020

Read More 'DVA' Stories Here

DVA Price Returns

1-mo 2.73%
3-mo 2.96%
6-mo 22.29%
1-year 52.92%
3-year 51.14%
5-year 19.63%
YTD 19.55%
2019 45.80%
2018 -28.78%
2017 12.54%
2016 -7.90%
2015 -7.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8151 seconds.